Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1998 3
1999 3
2000 2
2001 1
2003 2
2004 1
2005 3
2006 2
2007 1
2009 5
2010 5
2011 4
2012 2
2013 3
2014 4
2015 8
2016 12
2017 17
2018 13
2019 10
2020 7
2021 10
2022 8
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 31184238

108 results

Results by year

Filters applied: . Clear all
Page 1
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
Pillai V, Muralidharan K, Meng W, Bagashev A, Oldridge DA, Rosenthal J, Van Arnam J, Melenhorst JJ, Mohan D, DiNofia AM, Luo M, Cherian S, Fromm JR, Wertheim G, Thomas-Tikhonenko A, Paessler M, June CH, Luning Prak ET, Bhoj VG, Grupp SA, Maude SL, Rheingold SR. Pillai V, et al. Blood Adv. 2019 Nov 26;3(22):3539-3549. doi: 10.1182/bloodadvances.2019000692. Blood Adv. 2019. PMID: 31738832 Free PMC article.
Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
Mikhailova E, Semchenkova A, Illarionova O, Kashpor S, Brilliantova V, Zakharova E, Zerkalenkova E, Zangrando A, Bocharova N, Shelikhova L, Diakonova Y, Zhogov V, Khismatullina R, Molostova O, Buldini B, Raykina E, Larin S, Olshanskaya Y, Miakova N, Novichkova G, Maschan M, Popov AM. Mikhailova E, et al. Br J Haematol. 2021 May;193(3):602-612. doi: 10.1111/bjh.17382. Epub 2021 Mar 14. Br J Haematol. 2021. PMID: 33715150
Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia.
Dourthe ME, Rabian F, Yakouben K, Chevillon F, Cabannes-Hamy A, Méchinaud F, Grain A, Chaillou D, Rahal I, Caillat-Zucman S, Lesprit E, Naudin J, Roupret-Serzec J, Parquet N, Brignier A, Guérin-El Khourouj V, Lainey E, Caye-Eude A, Cavé H, Clappier E, Mathis S, Azoulay E, Dalle JH, Dhédin N, Madelaine I, Larghero J, Boissel N, Baruchel A. Dourthe ME, et al. Leukemia. 2021 Dec;35(12):3383-3393. doi: 10.1038/s41375-021-01281-7. Epub 2021 May 17. Leukemia. 2021. PMID: 34002027
Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
Verbeek MWC, Buracchi C, Laqua A, Nierkens S, Sedek L, Flores-Montero J, Hofmans M, Sobral de Costa E, Nováková M, Mejstrikova E, Barrena S, Kohlscheen S, Szczepanowski M, Kulis J, Oliveira E, Jugooa R, de Jong AX, Szczepanski T, Philippé J, van Dongen JJM, Orfao A, Brüggemann M, Gaipa G, van der Velden VHJ. Verbeek MWC, et al. Br J Haematol. 2022 Apr;197(1):76-81. doi: 10.1111/bjh.17992. Epub 2021 Dec 8. Br J Haematol. 2022. PMID: 34881427 Free PMC article.
B-lineage antigens that are useful to substitute CD19 for minimal residual disease monitoring in B cell precursor acute lymphoblastic leukemia after CD19 targeting.
Mikhailova E, Itov A, Zerkalenkova E, Roumiantseva J, Olshanskaya Y, Karachunskiy A, Novichkova G, Maschan M, Popov A. Mikhailova E, et al. Cytometry B Clin Cytom. 2022 Sep;102(5):353-359. doi: 10.1002/cyto.b.22088. Epub 2022 Jul 7. Cytometry B Clin Cytom. 2022. PMID: 35796438 Free article.
108 results